187 related articles for article (PubMed ID: 20680802)
1. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.
Kandalaft LE; Motz GT; Busch J; Coukos G
Curr Top Microbiol Immunol; 2011; 344():129-48. PubMed ID: 20680802
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
Kandalaft LE; Motz GT; Duraiswamy J; Coukos G
Cancer Metastasis Rev; 2011 Mar; 30(1):141-51. PubMed ID: 21298574
[TBL] [Abstract][Full Text] [Related]
3. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
4. Targeting VEGF/VEGFR to Modulate Antitumor Immunity.
Yang J; Yan J; Liu B
Front Immunol; 2018; 9():978. PubMed ID: 29774034
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
Pradeep CR; Sunila ES; Kuttan G
Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
[TBL] [Abstract][Full Text] [Related]
6. Calreticulin promotes tumor lymphocyte infiltration and enhances the antitumor effects of immunotherapy by up-regulating the endothelial expression of adhesion molecules.
Wang HT; Lee HI; Guo JH; Chen SH; Liao ZK; Huang KW; Torng PL; Hwang LH
Int J Cancer; 2012 Jun; 130(12):2892-902. PubMed ID: 21805477
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process.
Barbera-Guillem E; Nyhus JK; Wolford CC; Friece CR; Sampsel JW
Cancer Res; 2002 Dec; 62(23):7042-9. PubMed ID: 12460925
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor--a positive and negative regulator of tumor growth.
Vecchiarelli-Federico LM; Cervi D; Haeri M; Li Y; Nagy A; Ben-David Y
Cancer Res; 2010 Feb; 70(3):863-7. PubMed ID: 20103650
[TBL] [Abstract][Full Text] [Related]
9. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells.
Fainaru O; Almog N; Yung CW; Nakai K; Montoya-Zavala M; Abdollahi A; D'Amato R; Ingber DE
FASEB J; 2010 May; 24(5):1411-8. PubMed ID: 20008545
[TBL] [Abstract][Full Text] [Related]
10. [Vascular endothelial growth factor. From basic research to clinical application].
Smirne C; Camandona M; Rosso E; Bellone G; Emanuelli G
Minerva Med; 1999; 90(1-2):15-23. PubMed ID: 10388459
[TBL] [Abstract][Full Text] [Related]
11. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
Zhang L; Yang N; Park JW; Katsaros D; Fracchioli S; Cao G; O'Brien-Jenkins A; Randall TC; Rubin SC; Coukos G
Cancer Res; 2003 Jun; 63(12):3403-12. PubMed ID: 12810677
[TBL] [Abstract][Full Text] [Related]
12. Suppression of vascular endothelial growth factor abrogates the immunosuppressive capability of murine gastric cancer cells and elicits antitumor immunity.
Shi Y; Yu P; Zeng D; Qian F; Lei X; Zhao Y; Tang B; Hao Y; Luo H; Chen J; Tan Y
FEBS J; 2014 Sep; 281(17):3882-93. PubMed ID: 25041128
[TBL] [Abstract][Full Text] [Related]
13. Decorin suppresses tumor cell-mediated angiogenesis.
Grant DS; Yenisey C; Rose RW; Tootell M; Santra M; Iozzo RV
Oncogene; 2002 Jul; 21(31):4765-77. PubMed ID: 12101415
[TBL] [Abstract][Full Text] [Related]
14. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
15. CD40-induced countercurrent conduits for tumor escape or elimination?
Murugaiyan G; Martin S; Saha B
Trends Immunol; 2007 Nov; 28(11):467-73. PubMed ID: 17981086
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic active immunotherapy: a new approach to cancer treatment.
Pan J; Jin P; Yan J; Kabelitz D
Cancer Immunol Immunother; 2008 Aug; 57(8):1105-14. PubMed ID: 18214475
[TBL] [Abstract][Full Text] [Related]
17. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
Guo Y; Wang S; Hoot DR; Clinton SK
J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
[TBL] [Abstract][Full Text] [Related]
18. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
19. Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.
Strauss L; Volland D; Kunkel M; Reichert TE
Med Sci Monit; 2005 Aug; 11(8):BR280-92. PubMed ID: 16049374
[TBL] [Abstract][Full Text] [Related]
20. Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1.
Wang YS; Wang GQ; Wen YJ; Wang L; Chen XC; Chen P; Kan B; Li J; Huang C; Lu Y; Zhou Q; Xu N; Li D; Fan LY; Yi T; Wu HB; Wei YQ
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6779-87. PubMed ID: 18006780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
